Ras Isoprenylation and PAkt Inhibition by Zoledronic Acid and Fluvastatin Enhances Paclitaxel Activity in T24 Bladder Cancer Cells

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2013 Nov 12

PMID 24212635

Citations 7

Authors

Shaojuan Li

Paul de Souza

Affiliations

Soon will be listed here.

Abstract

Background: Bisphosphonates interfere with the mevalonate pathway and inhibit the prenylation of small GTP-binding proteins such as ras and rap. We hypothesized that zoledronic acid would synergistically inhibit T24 bladder cancer cell growth in combination with fluvastatin and paclitaxel.

Methods: Increasing doses of fluvastatin, zoledronic acid, and paclitaxel were investigated as single agents and in combination, and synergistic interactions were evaluated by the Chou-Talalay method. Western blots were used to assess effects on signal transduction pathways.

Results: Growth of T24 was significantly inhibited with IC50 values of 2.67 ± 0.61 mM for fluvastatin and 5.35 ± 1.35 mM for zoledronic acid after 72 hours treatment. Geranylgeranyl pyrophosphate and farnesyl pyrophosphate was able to block, in part, this inhibitory activity. The combinations of zoledronic acid and paclitaxel, zoledronic acid and fluvastatin, and fluvastatin and paclitaxel were all synergistic. Both fluvastatin and zoledronic acid inhibited Ras and Rap prenylation, and the phosphorylation of ERK1/2 and AKT. The degree of inhibition of phosphorylation of these key signaling transduction pathways appears to closely correlate with their synergistic interactions.

Conclusions: Zoledronic acid enhances fluvastatin and paclitaxel activity against T24 in a synergistic manner and this is mediated largely by inhibition of both the Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways via isoprenylation inhibition.

Citing Articles

Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization.

Wang G, Peng T, Chen L, Xiong K, Ju L, Qian K Commun Biol. 2024; 7(1):1476.

PMID: 39521858 PMC: 11550803. DOI: 10.1038/s42003-024-07067-8.

Two Main Cancer Biomarkers as Molecular Targets of Binase Antitumor Activity.

Dudkina E, Ulyanova V, Asmandiyarova V, Vershinina V, Ilinskaya O Biomed Res Int. 2024; 2024:8159893.

PMID: 38374954 PMC: 10876309. DOI: 10.1155/2024/8159893.

GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway.

Zhang W, Tang X, Peng Y, Xu Y, Liu L, Liu S Int J Oncol. 2024; 64(4).

PMID: 38334171 PMC: 10901536. DOI: 10.3892/ijo.2024.5622.

Prediction of putative small molecules for manipulation of enriched signalling pathways in hESC-derived early cardiovascular progenitors by bioinformatics analysis.

Vahdat S, Bakhshandeh B IET Syst Biol. 2021; 13(2):77-83.

PMID: 33444476 PMC: 8687323. DOI: 10.1049/iet-syb.2018.5037.

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells.

Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N Nat Commun. 2017; 8:15663.

PMID: 28580927 PMC: 5465356. DOI: 10.1038/ncomms15663.

References

Khosravi-Far R, Cox A, Kato K, Der C . Protein prenylation: key to ras function and cancer intervention?. Cell Growth Differ. 1992; 3(7):461-9. View

Kusama T, Mukai M, Tatsuta M, Matsumoto Y, Nakamura H, Inoue M . Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clin Exp Metastasis. 2003; 20(6):561-7. DOI: 10.1023/a:1025898316728. View

Eastman R, Buckner F, Yokoyama K, Gelb M, Van Voorhis W . Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res. 2005; 47(2):233-40. DOI: 10.1194/jlr.R500016-JLR200. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Olderoy G, Daehlin L, Ogreid D . Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res. 1998; 18(4A):2675-8. View

Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y . Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets. 2008; 8(1):27-36. DOI: 10.2174/156800908783497140. View

Guo R, Cao R, Liang P, Ko T, Chang T, Hudock M . Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007; 104(24):10022-7. PMC: 1877987. DOI: 10.1073/pnas.0702254104. View

Hu C, Kariya K, Okada T, Qi X, Song C, Kataoka T . Effect of phosphorylation on activities of Rap1A to interact with Raf-1 and to suppress Ras-dependent Raf-1 activation. J Biol Chem. 1998; 274(1):48-51. DOI: 10.1074/jbc.274.1.48. View

Caron R, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y . Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther. 2005; 4(2):257-70. View

10.

Reddy E, Reynolds R, Santos E, Barbacid M . A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 1982; 300(5888):149-52. DOI: 10.1038/300149a0. View

11.

Zhang F, Casey P . Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I. Biochem J. 1996; 320 ( Pt 3):925-32. PMC: 1218017. DOI: 10.1042/bj3200925. View

12.

Chen J, Horwitz S . Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res. 2002; 62(7):1935-8. View

13.

Szabo C, Matsumura Y, Fukura S, Martin M, Sanders J, Sengupta S . Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem. 2002; 45(11):2185-96. DOI: 10.1021/jm010412y. View

14.

Adamson P, Marshall C, Hall A, Tilbrook P . Post-translational modifications of p21rho proteins. J Biol Chem. 1992; 267(28):20033-8. View

15.

Saito S, Hata M, Fukuyama R, Sakai K, Kudoh J, Tazaki H . Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int J Urol. 1997; 4(2):178-85. DOI: 10.1111/j.1442-2042.1997.tb00167.x. View

16.

Jagdev S, Coleman R, Shipman C, Croucher P . The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001; 84(8):1126-34. PMC: 2363858. DOI: 10.1054/bjoc.2001.1727. View

17.

Fontana D, Bellina M, Scoffone C, Cagnazzi E, Cappia S, Cavallo F . Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol. 1996; 29(4):470-6. DOI: 10.1159/000473799. View

18.

Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf C . Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer. 2001; 85(8):1175-84. PMC: 2375166. DOI: 10.1054/bjoc.2001.2044. View

19.

Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye J . Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer. 2006; 6:60. PMC: 1434759. DOI: 10.1186/1471-2407-6-60. View

20.

Danesi R, Figg W, Reed E, Myers C . Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol. 1995; 47(6):1106-11. View